Other Events ·
On July 15, 2026, Lakewood-Amedex Biotherapeutics Inc. released a corporate investor presentation detailing its…
LABTLakewood-Amedex Biotherapeutics Inc.
On July 15, 2026, Lakewood-Amedex Biotherapeutics Inc. released a corporate investor presentation detailing its Bisphosphocin® compounds, a novel class of fast-acting, broad-spectrum antimicrobials. The company highlighted its lead program, Nu-3, a topical antimicrobial gel for treating infected diabetic foot ulcers (iDFU), which has an open IND. Key upcoming milestones include the commencement of a clinical trial in 3Q26, with top-line results expected in 4Q26 or 1Q27. The company's intellectual property portfolio includes 101 patents with protection extending through 2044. The company is a clinical-stage biotechnology company developing antimicrobials to treat infectious diseases and combat antibiotic resistance.